Chemistry:Aumolertinib
From HandWiki
Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer.[1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).[2]
In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.[3][4]
Society and culture
Legal status
In December 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aumseqa, intended for the treatment of non-small cell lung cancer (NSCLC).[5] The applicant for this medicinal product is SFL Pharmaceuticals Deutschland GmbH.[5]
References
- ↑ "Aumolertinib: A Review in Non-Small Cell Lung Cancer". Drugs 82 (5): 577–584. April 2022. doi:10.1007/s40265-022-01695-2. PMID 35305259. https://figshare.com/articles/online_resource/Aumolertinib_A_Review_in_Non-Small_Cell_Lung_Cancer/19166432.
- ↑ "Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE)". Journal of Clinical Oncology 41 (16). 2023. doi:10.1200/JCO.2023.41.16_suppl.TPS9153.
- ↑ "Almonertinib Approved in China for EGFR T79M+ NSCLC". March 19, 2020. https://www.onclive.com/view/almonertinib-approved-in-china-for-emegfrem-t79m-nsclc.
- ↑ "Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial". Journal of Thoracic Oncology 17 (3): 411–422. March 2022. doi:10.1016/j.jtho.2021.10.024. PMID 34801749.
- ↑ 5.0 5.1 "Aumseqa EPAR". 12 December 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/aumseqa. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
 |  |
